MARTIN R FARLOW, MD
Neurology at University Blvd, Indianapolis, IN
License number
Indiana 01029454A
Category
Neurology
Type
Neurology
Address
Address
550 University Blvd, Indianapolis, IN 46202
Phone
(317) 274-8800
Personal information
See more information about MARTIN R FARLOW at radaris.comName
Address
Phone
5049 Potters Pike, Indianapolis, IN 46234
Indianapolis, IN
5049 Potters Pike, Indianapolis, IN 46234
Organization information
See more information about MARTIN R FARLOW at bizstanding.comMartin R Farlow MD
355 W 16 St STE 3200, Indianapolis, IN 46202
Categories:
Neurology Physicians & Surgeons
Phone:
(317) 948-5450 (Phone)
Professional information
Martin R Farlow, Indianapolis IN
Specialties:
Neurologist
Address:
545 Barnhill Dr, Indianapolis, IN 46202
550 University Blvd, Indianapolis, IN 46202
541 Clinical Dr, Indianapolis, IN 46202
550 University Blvd, Indianapolis, IN 46202
541 Clinical Dr, Indianapolis, IN 46202
Education:
Indiana University, School of Medicine - Doctor of Medicine
Board certifications:
American Board of Psychiatry and Neurology Certification in Neurology (Psychiatry and Neurology)
Dr. Martin R Farlow, Indianapolis IN - MD (Doctor of Medicine)
Specialties:
Neurology, Neuropsychiatry (Neurology)
Address:
541 Clinical Dr SUITE 291, Indianapolis 46202
(317) 278-0270 (Phone)
545 Barnhill Dr SUITE 125, Indianapolis 46202
545 Barnhill Dr SUITE EH125, Indianapolis 46202
(317) 274-8800 (Phone)
University Clinical Neurology
550 University Blvd SUITE 1710, Indianapolis 46202
(317) 278-0270 (Phone)
(317) 278-0270 (Phone)
545 Barnhill Dr SUITE 125, Indianapolis 46202
545 Barnhill Dr SUITE EH125, Indianapolis 46202
(317) 274-8800 (Phone)
University Clinical Neurology
550 University Blvd SUITE 1710, Indianapolis 46202
(317) 278-0270 (Phone)
Certifications:
Neurology, 1988
Awards:
Healthgrades Honor Roll
Languages:
English, Spanish
Education:
Medical School
Indiana University School Of Medicine
Graduated: 1979
Ind University Hospital
Graduated: 1980
Graduated: 1983
Indiana University School Of Medicine
Graduated: 1979
Ind University Hospital
Graduated: 1980
Graduated: 1983
Methods For Stimulation Of Synthesis Of Synaptophysin In The Central Nervous System
US Patent:
2002004, Apr 4, 2002
Filed:
Jul 5, 2001
Appl. No.:
09/899478
Inventors:
Michelle Glasky - Irvine CA, US
Debomoy Lahiri - Indianapolis IN, US
Martin Farlow - Indianapolis IN, US
Debomoy Lahiri - Indianapolis IN, US
Martin Farlow - Indianapolis IN, US
International Classification:
A61K031/522, A61K031/505, A61K031/404
US Classification:
514/263350, 514/263200, 514/256000, 514/414000, 514/415000
Abstract:
A method of increasing the synthesis and/or secretion of synaptophysin comprises administering to a patient with a neurological disease or a patient at risk of developing a neurological disease an effective quantity of a purine derivative or analogue, a tetrahydroindolone derivative or analogue, or a pyrimidine derivative or analogue. If the compound is a purine derivative, the purine moiety can be guanine or hypoxanthine. The neurological disease can be a neurodegenerative disease such as Alzheimer's disease or a neurodevelopmental disorder such as Down's syndrome. Typically, the compound can pass through the blood-brain barrier. The purine moiety can be hypoxanthine or guanine. A particularly preferred purine derivative is N-4-carboxyphenyl-3-(6-oxohydropurin-9-yl) propanamide.
Methods For Prevention Of Accumulation Of Amyloid Beta Peptide In The Central Nervous System
US Patent:
2002004, Apr 4, 2002
Filed:
Jul 5, 2001
Appl. No.:
09/899611
Inventors:
Michelle Glasky - Irvine CA, US
Debomoy Lahiri - Indianapolis IN, US
Martin Farlow - Indianapolis IN, US
Debomoy Lahiri - Indianapolis IN, US
Martin Farlow - Indianapolis IN, US
International Classification:
A61K031/522, A61K031/505, A61K031/404
US Classification:
514/263000, 514/256000, 514/419000
Abstract:
A method of either inhibiting the formation of A or stimulating the formation of sAPP comprises administering to a patient with a neurological disease or a patient at risk of developing a neurological disease an effective quantity of a purine derivative or analogue, a tetrahydroindolone derivative or analogue, or a pyrimidine derivative or analogue. If the compound is a purine derivative, the purine moiety can be guanine or hypoxanthine. The neurological disease can be a neurodegenerative disease such as Alzheimer's disease or a neurodevelopmental disorder such as Down's syndrome. Typically, the compound can pass through the blood-brain barrier. The purine moiety can be hypoxanthine or guanine. A particularly preferred purine derivative is N-4-carboxyphenyl-3-(6-oxohydropurin-9-yl) propanamide.
Methods And Compositions For Diagnosing Tauopathies
US Patent:
2002001, Feb 14, 2002
Filed:
Nov 29, 2000
Appl. No.:
09/726771
Inventors:
Bernardino Ghetti - Indianapolis IN, US
Maria Spillantini - Cambridge, GB
Jill Murrell - Avon IN, US
Michel Goedert - Cambridge, GB
Martin Farlow - Indianapolis IN, US
Aaron Klug - Cambridge, GB
Maria Spillantini - Cambridge, GB
Jill Murrell - Avon IN, US
Michel Goedert - Cambridge, GB
Martin Farlow - Indianapolis IN, US
Aaron Klug - Cambridge, GB
Assignee:
Advanced Research and Technology
International Classification:
C12Q001/68, G01N033/567, G01N033/53, G01N033/537, G01N033/543
US Classification:
435/006000, 435/007210, 435/007920
Abstract:
The present invention relates generally to methods and compositions for the diagnosis, modeling and treatment of tau-related pathologies. In particular, the present invention shows that mutations in the tau gene lead to neurofibrillary tangle formation. More specifically gene mutations are described that lead to alterations in ratios of tau isoforms are shown to lead to the formation of abnormal tau filaments.
Transgenic Mouse Expressing App770-V717F
US Patent:
6184435, Feb 6, 2001
Filed:
Jun 7, 1995
Appl. No.:
8/475176
Inventors:
Merrill D. Benson - Indianapolis IN
Jill Murrell - Indianapolis IN
Martin Farlow - Indianapolis IN
Bernardino Ghetti - Indianapolis IN
Jill Murrell - Indianapolis IN
Martin Farlow - Indianapolis IN
Bernardino Ghetti - Indianapolis IN
Assignee:
Advanced Research and Technology Institute - Bloomington IN
International Classification:
A01K 67027, A01K 67033, G01N 3300
US Classification:
800 18
Abstract:
Methods for screening for risk of Alzheimer's disease involve assaying for a guanine to thymine substitution at position 1924 of the gene encoding the human amyloid precursor protein. Also described are transgenic non-human mammals, especially transgenic mice, harboring an expressable gene sequence encoding human amyloid precursor protein having a phenyalanine for valine amino acid substitution in the transmembrane domain of the amyloid precursor protein.
Use Of 1-Aminocyclohexane Derivatives To Modify Deposition Of Fibrillogenic A-Beta Peptides In Amyloidopathies
US Patent:
2005011, May 26, 2005
Filed:
Oct 22, 2004
Appl. No.:
10/971306
Inventors:
Sandeep Gupta - Plainsboro NJ, US
Pradeep Banerjee - Hillsborough NJ, US
Debomoy Lahiri - Indianapolis IN, US
Martin Farlow - Indianapolis IN, US
Pradeep Banerjee - Hillsborough NJ, US
Debomoy Lahiri - Indianapolis IN, US
Martin Farlow - Indianapolis IN, US
Assignee:
Forest Laboratories, Inc. - New York NY
International Classification:
A61K031/13
US Classification:
514659000
Abstract:
The invention relates to the use of NMDA receptor antagonists such as 1-aminocyclohexane derivatives to modify deposition of potentially toxic and fibrillogenic Aβ peptides in amyloidopathies. Specifically, the invention relates to the ability of memantine to intervene in the processing of APP and decrease the levels of fibrillogenic Aβ peptides.
Method For Screening For Alzheimer's Disease
US Patent:
5879883, Mar 9, 1999
Filed:
May 3, 1995
Appl. No.:
8/434018
Inventors:
Merrill D. Benson - Indianapolis IN
Jill Murrell - Indianapolis IN
Martin Farlow - Indianapolis IN
Bernardino Ghetti - Indianapolis IN
Jill Murrell - Indianapolis IN
Martin Farlow - Indianapolis IN
Bernardino Ghetti - Indianapolis IN
Assignee:
Indiana University Foundation - Bloomington IN
International Classification:
C12Q 168, C12N 1511, C07H 2104
US Classification:
435 6
Abstract:
Method for screening for risk of Alzheimer's disease involve assaying for a guanine to thymine substitution at position 1924 of the gene encoding the human amyloid precursor protein. Also described are transgenic mammals harboring an expressable gene sequence encoding human amyloid precursor protein having a phenyanine for valine amino acid substitution in the transmembrane domain of the amyloid precursor protein.
Treatment Of Neurodegenerative And Cardiovascular Disorders
US Patent:
8575215, Nov 5, 2013
Filed:
Feb 18, 2010
Appl. No.:
12/708401
Inventors:
Yangsheng Du - Westfield IN, US
Martin R. Farlow - Indianapolis IN, US
Ruyu Du - Carmel IN, US
Martin R. Farlow - Indianapolis IN, US
Ruyu Du - Carmel IN, US
International Classification:
A61K 31/235
US Classification:
514544, 514543
Abstract:
A method of treating a neurodegenerative or cardiovascular disorder with a compound of the following formula:.
Treatment Of Neurodegenerative And Cardiovascular Disorders
US Patent:
2003013, Jul 24, 2003
Filed:
Dec 10, 2002
Appl. No.:
10/316145
Inventors:
Yansheng Du - Carmel IN, US
Martin Farlow - Indianapolis IN, US
Ruyu Du - Carmel IN, US
Martin Farlow - Indianapolis IN, US
Ruyu Du - Carmel IN, US
International Classification:
A61K031/44, A61K031/277, A61K031/40, A61K031/21, A61K031/16, A61K031/165
US Classification:
514/357000, 514/408000, 514/513000, 514/521000, 514/599000, 514/617000
Abstract:
A method of treating a neurodegenerative or cardiovascular disorder with a compound of the following formula:
in which X, Y, A, A, R, and Rare defined herein.